APUS on NYSE
Apimeds Pharmaceuticals US, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development expenses | $1.6M | |
| General and administrative expenses | $10.3M | $1.3M |
| Total operating expenses | $11.9M | $1.3M |
| Loss from operations | -$11.9M | -$1.3M |
| Unrealized gain from changes in fair value of digital assets | $1.8M | |
| Realized gain on sale of digital assets | $4.2M | |
| Trading gains, net | $97 | |
| Foreign currency gains/(losses), net | -$521 | |
| Change in FV of warrant liability | $22.4K | |
| Change in FV of derivative | $55.1K | |
| Interest income | $107.6K | $2.8K |
| Interest expense | -$283.0K | -$117.7K |
| Total other income (expense) | $5.9M | -$114.9K |
| Net loss | -$6.0M | -$1.4M |
| Net loss per common share - basic (in Dollars per share) | -$0.55 | -$0.18 |
| Net loss per common share - diluted (in Dollars per share) | -$0.55 | -$0.18 |
| Weighted average common shares outstanding - basic (in Shares) | 10.9M shares | 7.9M shares |
| Weighted average common shares outstanding - Diluted (in Shares) (in Shares) | 10.9M shares | 7.9M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash & Cash Equivalents | $1.6M | $3.5K | |
| Restricted Cash | $8.0M | ||
| Short Term Investments | $2.0M | ||
| Prepaid Expenses | $2.3M | $9.6K | |
| Other Current Assets | $48.5K | ||
| Total current assets | $14.0M | $13.1K | |
| Digital assets, at fair value | $149.9M | ||
| Long-term portion of prepaid expenses | $75.5K | ||
| Operating Lease ROU Asset | $187.4K | ||
| Property and Equipment, net | $51.6K | ||
| Total assets | $164.2M | $13.1K | |
| Accounts payable and accrued expenses | $918.6K | $591.2K | |
| Accrued offering costs | $500.0K | ||
| Accrued interest - related party | $28.0K | $106.6K | |
| Advance payable to related party | $12.0K | $76.5K | |
| Notes payable - related party | $500.1K | $250.0K | |
| Derivative Liability | $1.6M | ||
| Convertible Notes, net | $7.1M | ||
| Operating Lease Liability | $39.6K | ||
| Total current liabilities | $10.7M | $1.0M | |
| Long-Term Portion of Operating Lease Liability | $129.5K | ||
| Long-term convertible notes payable related party | $346.8K | ||
| Total liabilities | $10.8M | $1.4M | |
| Preferred stock, par value $0.01, 10,000,000 shares authorized: 7,477,017 and none issued and outstanding at December 31,2025 and 2024, respectively | $74.8K | ||
| Common stock, par value $0.01, 100,000,000 shares authorized; 12,575,983 and 7,903,850 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $125.8K | $79.0K | |
| Additional paid-in capital | $163.5M | $3.0M | |
| Retained Earnings (Deficit) | -$10.4M | -$4.4M | |
| Total shareholders equity (deficit) | $153.3M | -$1.4M | $31.9K |
| Total liabilities and shareholders equity | $164.2M | $13.1K | |
| Preferred stock, par value (in Dollars per share) | $0.01 | $0.01 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in Shares) | 7.5M shares | ||
| Preferred stock, shares outstanding (in Shares) | 7.5M shares | ||
| Common stock, par value (in Dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 12.6M shares | 7.9M shares | |
| Common stock, shares outstanding (in Shares) | 12.6M shares | 7.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$6.0M | -$1.4M |
| Stock based compensation - Common Stock Grants | $1.7M | |
| Stock based compensation - stock options and warrants | $1.6M | |
| Change in fair value of warrant liability | -$22.4K | |
| Change in fair value of derivative liability | -$55.1K | |
| Depreciation expense | $5.7K | |
| Interest expense | $283.0K | $117.7K |
| Unrealized gain from changes in fair value of digital assets | -$6.0M | |
| Non-cash digital asset operating expenses | $2.4M | |
| Prepaid expenses and other current assets | -$2.4M | $2.0K |
| Deferred offering costs related to the merger | -$408.2K | $536.8K |
| Net cash used in operating activities | -$8.9M | -$733.5K |
| Cash from short term investments | -$2.0M | |
| Restricted cash | -$8.0M | |
| Purchases of PP&E | -$57.3K | |
| Cash paid to acquire operating lease | -$18.4K | |
| Cash acquired in accordance with merger | $15.3K | |
| Net cash used in investing activities | -$10.1M | |
| Cash proceeds from issuance of common stock in IPO | $11.6M | |
| Proceeds from notes payable - related parties | $250.1K | $250.0K |
| Proceeds from PIPE convertible note | $10.0M | |
| Payment of debt issuance costs | -$946.0K | |
| Cash advances from related parties | $29.3K | $76.5K |
| Cash advances paid to related parties | -$343.8K | |
| Net cash provided by financing activities | $20.6M | $326.5K |
| Net increase (decrease) in cash, cash equivalents | $1.6M | -$407.0K |
| Net Assets Acquired in the Merger | $15.3K | |
| Operating Lease | -$18.4K |
Compare Apimeds Pharmaceuticals US, Inc. with another company
Recent filings
- Oct 13, 20268-K CURRENT REPORT
- Oct 1, 20268-K CURRENT REPORT
- Sep 29, 20268-K CURRENT REPORT
- Sep 23, 20268-K CURRENT REPORT
- Sep 11, 20268-K CURRENT REPORT
- Aug 21, 20268-K CURRENT REPORT
- Aug 14, 202610-Q QUARTERLY REPORT
- Aug 6, 20268-K CURRENT REPORT
- Jul 13, 20268-K CURRENT REPORT
- May 26, 202610-Q QUARTERLY REPORT
- May 15, 2026NT 10-Q NOTIFICATION OF LATE FILING
- May 7, 2026SCHEDULE 13D/A
- May 5, 20268-K CURRENT REPORT
- May 4, 20268-K CURRENT REPORT
- May 4, 202610-K ANNUAL REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6